Tabrecta for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations
Quick answer: Tabrecta is used for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations as part of a met kinase inhibitor treatment regimen. Selective tyrosine kinase inhibitor of MET receptor blocking oncogenic MET signaling The specific dosing for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations is determined by your prescriber based on individual factors.
Why is Tabrecta used for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations?
Tabrecta belongs to the MET kinase inhibitor class. Selective tyrosine kinase inhibitor of MET receptor blocking oncogenic MET signaling This action makes it useful for treating or managing Metastatic non-small cell lung cancer with MET exon 14 skipping mutations in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Tabrecta is the right choice for a specific patient depends on the type and severity of Metastatic non-small cell lung cancer with MET exon 14 skipping mutations, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations
Common adult dosing range: 400 mg orally twice daily. The actual dose for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Tabrecta medicine page.
What to expect
Tabrecta treatment for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Metastatic non-small cell lung cancer with MET exon 14 skipping mutations
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Tabrecta is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all MET kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Tabrecta
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Tabrecta full prescribing information · All MET kinase inhibitor alternatives
Frequently asked questions
How effective is Tabrecta for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations?
Effectiveness varies by individual response, dose, and severity. Tabrecta is one of several treatment options for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations, supported by clinical evidence within the met kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Tabrecta for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations?
Treatment duration depends on the nature of Metastatic non-small cell lung cancer with MET exon 14 skipping mutations — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Tabrecta when used for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Tabrecta for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations?
Yes. Multiple medicines and non-drug options exist for Metastatic non-small cell lung cancer with MET exon 14 skipping mutations. Alternatives within the met kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.